(2)
Collaboration focuses on up to three types of lung and gastrointestinal (GI) cancers
Latest in a series of strategic acquisitions and partnerships that strengthens Boehringer Ingelheim s position in the cancer vaccine and T-cell engager spaces
Agreement and partnership with Boehringer Ingelheim provides additional validation of Enara Bio s EDAPT platform and Dark Antigen discovery work and supports ongoing cell therapy based therapeutic approach
Boehringer Ingelheim and Enara Bio, today announced that they have entered into a strategic collaboration and licensing agreement to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio s Dark Antigen discovery platform. This new collaboration combines Boehringer Ingelheim s approach to tackle cancer through pairing leading science with innovative immune-oncology platforms, such as oncolytic viruses and cancer vaccines, with Enara Bio s expertise in cancer antigen identification. The aim is to provide poten
A new startup is working towards using a patient’s own genetic makeup to fight cancer.
Catamaran Bio, a startup at LabCentral in Cambridge, was established to consider the potency of natural killer (NK) cells in fighting cancer, and so far, it has raised $42 million from five venture capital companies including the founding investor, SV Health Investors, of Boston.
“This was a group of people who had wanted to do something together for a long time,” said Houman Ashrafian, managing partner of SV Health Investors.
Immunotherapy drugs such as Kymriah, Novartis’s leukemia therapy, have shown promising results for the treatment of blood cancers. The approach, also called CAR-T therapy, relies on harvesting patients’ T cells and genetically altering them to target the cancer after they are reintegrated into the patient’s genetic makeup. Earlier in 2020, researchers at MD Anderson Cancer Centre announced they achieved a “73% response rate with a CD19-targeting therapy d